Diagnostic Efficiency by Gentian - Newsletter H1-2020

14. Jan 2020 | 11 min read

Diagnostic Efficiency by Gentian - Newsletter H1-2020
 

Happy New Year 2020

We look forward to exhibiting at and visiting numerous trade shows and congresses around the world in 2020. You are most welcome to visit our booth to discuss diagnostic efficiency and learn more about our immunoassays at the different events.

For meeting bookings please email us 
marketing@gentian.com.

If you are based in the US you can meet us at NKF Spring Clinical Meetings (booth #233), AACC (booth #3874) and KidneyWeek (booth #339). We look forward to seeing you there. 

For more locations where you can meet the Gentian team and learn more about our products please follow the link below:

Meet Gentian in 2020
 

Gentian in the US

Gentian USA Inc. was established in 2012. The subsidiary has continuously grown it’s market share for the immunoassays Cystatin C and Canine CRP through routine clients and OEM partners.

In order to expand Gentian’s presence in the USA, we have during 2019, initiated a collaboration with BioHealth Innovation (BHI). The collaboration allows Gentian to support current and new US customers and OEM partners more closely, and will also make our high quality assays more visible to a larger US customer base.

 
Contact Gentian USA, Inc.
 

BioTalk Podcast 

Gentian’s CEO Dr Hilja Ibert, PhD, sat down with BioTalk host Rich Bendis, Founder, President and CEO BioHealth Innovation Inc. In this podcast you can hear Dr Ibert talk about Gentian’s presence in the US market, our biomarkers and how Gentian focuses on innovating diagnostic efficiency.

Listen to the podcast here.

 

Calprotectin as a sepsis marker and mortality predictor 


The newly published article “Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients” in the Scandinavian Journal of Clinical and Laboratory Investigation describes performance of calprotectin and procalcitonin in differentiation between ICU patients with sepsis and non-sepsis and prediction of 30-day mortality.
 
The results from the study indicate that calprotectin is superior to procalcitonin as a sepsis biomarker and predictor of 30-day mortality in intensive care patients. This article is based on the same study that was presented at the International Sepsis Forum in Bangkok in 2018

 

Read the full article here

 

The Gentian Calprotectin Immunoassay 

The Gentian Calprotectin Immunoassay is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro diagnostic testing of calprotectin in human plasma samples. The assay is performed in only 10 minutes and can be applied on a wide range of clinical chemistry analysers. 

CE marked
US: Research only

 
Learn more about calprotectin

 

You may also read


Collaboration Proposal - COVID-19

Apr 03, 2020

Collaboration Proposal - COVID-19

We at Gentian AS believe it is the duty of all companies in the health industry to help combat the ongoing..

Statement to Customers on COVID-19 Concerns

Mar 13, 2020

Statement to Customers on COVID-19 Concerns

At Gentian, the health and safety of our employees, as well as our customers and partners, is of primary..

New article about calprotectin in Scientific Reports

Mar 11, 2020

New article about calprotectin in Scientific Reports

Calprotectin, a new biomarker for diagnosis of acute respiratory infections*